Literature DB >> 27580616

Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis.

Sabahat Bokhari1, Rachelle Morgenstern2, Richard Weinberg2, Mona Kinkhabwala2, Demetrios Panagiotou2, Adam Castano2, Albert DeLuca2, Andrew Kontak2, Zhezhen Jin3, Mathew S Maurer2.   

Abstract

BACKGROUND: Technetium pyrophosphate (99mTc-PYP) imaging to diagnose transthyretin cardiac amyloidosis (ATTR-CA) has been increasingly utilized. The objective of this study is to provide a standardized 99mTc-PYP imaging protocol to diagnose ATTR-CA.
METHODS: 104 scans from 45 subjects with biopsy-proven ATTR-CA or light-chain cardiac amyloidosis (AL) were assessed. Multiple scans were obtained using different counts (750 vs 2000 K), times to acquisition (1 vs 2 to 4 hours), processing matrix (256 vs 128), and 99mTc-PYP dose. Image quality and extracardiac activity was assessed. Quantitative methods using heart-to-contralateral ratios (H/CL) and a visual semiquantitative scale were used to diagnose ATTR-CA.19 The correlation between H/CL ratios and reproducibility of semiquantitative visual scores, acquired using various imaging parameters, were evaluated.
RESULTS: All imaging parameters had good to excellent image quality. 750 vs 2000 K counts, 1 hour acquisition and 256 matrix, had lower extracardiac activity (P = .00018). 10 mCi of 99mTc-PYP v. higher doses showed excellent image quality and less extracardiac activity (P = .0015). Correlation of H/CL ratios was strong (r ≥ 0.92) and reproducibility of semiquantitative visual scores was high (Kappa = 95%).
CONCLUSION: An imaging protocol using 750 K counts, 10 mCi of 99mTc-PYP, and a 256 matrix was chosen as the standardized imaging protocol since it provided the shortest overall study time (1 vs 2 to 4 hours) and lowest radiation exposure (3 vs 8 to 10 mSv).

Entities:  

Keywords:  99mTc-PYP; ATTR-CA; amyloid; amyloidosis; non-invasive; standardized imaging protocol

Mesh:

Substances:

Year:  2016        PMID: 27580616     DOI: 10.1007/s12350-016-0610-4

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  27 in total

1.  Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).

Authors:  Frederick L Ruberg; Mathew S Maurer; Daniel P Judge; Steven Zeldenrust; Martha Skinner; Antony Y Kim; Rodney H Falk; Kin N Cheung; Ayan R Patel; Arian Pano; Jeffrey Packman; Donna Roy Grogan
Journal:  Am Heart J       Date:  2012-08       Impact factor: 4.749

Review 2.  Cardiac amyloidosis: the great pretender.

Authors:  Claudio Rapezzi; Massimiliano Lorenzini; Simone Longhi; Agnese Milandri; Christian Gagliardi; Ilaria Bartolomei; Fabrizio Salvi; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

3.  Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis.

Authors:  M A Gertz; M L Brown; M F Hauser; R A Kyle
Journal:  Arch Intern Med       Date:  1987-06

4.  Technetium-99m pyrophosphate single-photon emission computed tomography of the heart in familial amyloid polyneuropathy.

Authors:  K Karp; U Näslund; C Backman; P Eriksson
Journal:  Int J Cardiol       Date:  1987-03       Impact factor: 4.164

Review 5.  Molecular imaging of amyloidosis: will the heart be the next target after the brain?

Authors:  Wengen Chen; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2012-04       Impact factor: 2.931

6.  Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center.

Authors:  Raymond C Givens; Chris Russo; Philip Green; Mathew S Maurer
Journal:  Aging health       Date:  2013-04-01

7.  Soft-tissue uptake of 99mTc-diphosphonate and 99mTc-pyrophosphate in amyloidosis.

Authors:  S Janssen; D A Piers; M H van Rijswijk; S Meijer; E Mandema
Journal:  Eur J Nucl Med       Date:  1990

8.  Transthyretin cardiac amyloidoses in older North Americans.

Authors:  Kumar Dharmarajan; Mathew S Maurer
Journal:  J Am Geriatr Soc       Date:  2012-02-13       Impact factor: 5.562

9.  Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis.

Authors:  T A Wizenberg; J Muz; Y H Sohn; W Samlowski; A M Weissler
Journal:  Am Heart J       Date:  1982-04       Impact factor: 4.749

10.  A Routine PET/CT Protocol with Streamlined Calculations for Assessing Cardiac Amyloidosis Using (18)F-Florbetapir.

Authors:  Dustin R Osborne; Shelley N Acuff; Alan Stuckey; Jonathan S Wall
Journal:  Front Cardiovasc Med       Date:  2015-05-08
View more
  19 in total

1.  Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis.

Authors:  Andrew J Einstein; Igor Shuryak; Adam Castaño; Akiva Mintz; Mathew S Maurer; Sabahat Bokhari
Journal:  J Nucl Cardiol       Date:  2018-05-30       Impact factor: 5.952

2.  CPC Commentary on "Coexistence of cardiac amyloidosis with coronary artery disease and the challenges in medical management".

Authors:  Lawrence Phillips
Journal:  J Nucl Cardiol       Date:  2019-04-15       Impact factor: 5.952

3.  Use of fluorine-18 sodium fluoride for the diagnosis of transthyretin cardiac amyloidosis: The birth of a new technique.

Authors:  Cesia Gallegos; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2017-03-29       Impact factor: 5.952

4.  Technetium 99m pyrophosphate radioisotope for diagnosis and prognosis of transthyretin cardiac amyloidosis: A call for collaboration.

Authors:  Adam Castaño; Mathew S Maurer; Sabahat Bokhari
Journal:  J Nucl Cardiol       Date:  2017-02-01       Impact factor: 5.952

Review 5.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.

Authors:  Mathew S Maurer; Sabahat Bokhari; Thibaud Damy; Sharmila Dorbala; Brian M Drachman; Marianna Fontana; Martha Grogan; Arnt V Kristen; Isabelle Lousada; Jose Nativi-Nicolau; Candida Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Ronald Witteles; Giampaolo Merlini
Journal:  Circ Heart Fail       Date:  2019-09-04       Impact factor: 8.790

6.  ASNC imaging guidelines for nuclear cardiology procedures : Standardized reporting of nuclear cardiology procedures.

Authors:  Peter L Tilkemeier; Jamieson Bourque; Rami Doukky; Rupa Sanghani; Richard L Weinberg
Journal:  J Nucl Cardiol       Date:  2017-09-15       Impact factor: 5.952

7.  Refining risk in diabetes and CAD with SPECT MPI: New insights and future challenges.

Authors:  Syed Y Naqvi; Steven D Wittlin; Ronald G Schwartz
Journal:  J Nucl Cardiol       Date:  2018-02-05       Impact factor: 5.952

8.  Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis.

Authors:  Giorgio Treglia; Andor W J M Glaudemans; Francesco Bertagna; Bouke P C Hazenberg; Paola A Erba; Raffaele Giubbini; Luca Ceriani; John O Prior; Luca Giovanella; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-23       Impact factor: 9.236

Review 9.  Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies.

Authors:  Ilia G Halatchev; Jingsheng Zheng; Jiafu Ou
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

10.  A case report of an uncommon presentation of 99mtechnetium pyrophosphate scintigraphy in transthyretin cardiac amyloidosis: A potential diagnostic pitfall, pseudo-positive or pseudo-negative?

Authors:  Yuri Ochi; Toru Kubo; Yasuteru Nakashima; Asa Takahashi; Yuichi Baba; Takayoshi Hirota; Naohito Yamasaki; Hiroaki Kitaoka
Journal:  J Cardiol Cases       Date:  2019-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.